Novartis gains $487 million in funding for new influenza facility
This article was originally published in Scrip
Executive Summary
Novartishas secured $487 million to develop a cell-based influenza vaccine manufacturing facility in North Carolina. The funding comes from the US Department of Health and Human Services (HHS) and the Biomedical Advanced Research and Development Authority (BARDA).